Landscape of genomic alterations in cervical carcinomas

Nature (Impact Factor: 41.46). 12/2013; 506(7488). DOI: 10.1038/nature12881
Source: PubMed


Cervical cancer is responsible for 10-15% of cancer-related deaths in women worldwide. The aetiological role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is well established. Previous studies have also implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS as well as several copy-number alterations in the pathogenesis of cervical carcinomas. Here we report whole-exome sequencing analysis of 115 cervical carcinoma-normal paired samples, transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs. Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%). We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines (Tp*C sites) than adenocarcinomas. Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site. These data demonstrate several recurrent genomic alterations in cervical carcinomas that suggest new strategies to combat this disease.

Download full-text


Available from: María Lourdes Garza-Rodríguez, Feb 18, 2014
  • Source
    • "Genetic studies identified the short arm of chromosome 8 (8p) as a frequent target of nonrandom and recurrent deletion in cervical cancer (CC) (Mitra et al., 1994; Hampton et al., 1996; Harris et al., 2003; Bhattacharya et al., 2004; Rao et al., 2004; Kloth et al., 2007; Ojesina et al., 2014). These studies suggest the presence of tumor suppressor genes on 8p and their involvement in the development of CC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple chromosomal regions are affected by deletions in cervical cancer (CC) genomes, but their consequence and target gene involvement remains unknown. Our single nucleotide polymorphism (SNP) array identified 8p copy number losses localized to an 8.4 Mb minimal deleted region (MDR) in 36% of CC. The 8p MDR was associated with tumor size, treatment outcome, and with multiple HPV infections. Genetic, epigenetic, and expression analyses of candidate genes at MDR identified promoter hypermethylation and/or inactivation of decoy receptors TNFRSF10C and TNFRSF10D in the majority of CC patients. TNFRSF10C methylation was also detected in precancerous lesions suggesting that this change is an early event in cervical tumorigenesis. We further demonstrate here that CC cell lines exhibiting downregulated expression of TNFRSF10C and/or TNFRSF10D effectively respond to TRAIL-induced apoptosis and this affect was synergistic in combination with DNA damaging chemotherapeutic drugs. We show that the CC cell lines harboring epigenetic inactivation of TRAIL decoy receptors effectively activate downstream caspases suggesting a critical role of inactivation of these genes in efficient execution of extrinsic apoptotic pathway and therapy response. Therefore, these findings shed new light on the role of genetic/epigenetic defects in TRAIL decoy receptor genes in the pathogenesis of CC and provide an opportunity to explore strategies to test decoy receptor gene inactivation as a biomarker of response to Apo2L/TRAIL-combination therapy. © 2015 Wiley Periodicals, Inc.
    Full-text · Article · Nov 2015 · Genes Chromosomes and Cancer
  • Source
    • "Several cellular genes such as TP53 [10,11], PIK3CA [12], c-Myc (Myc) and ErbB2 [13], cIAP1 [14], Ras [15], PTEN [16] and LKB1 [17] have been found mutated or functional inactivated in variable proportions of cervical cancers. Comprehensive analysis of genomic aberrations in cervical tumors allowed to identify, besides the previously characterized mutations in TP53 and PIK3CA genes, unknown mutations in MAPK1, HLA-B, EP300, FBXW7, NFE2L2, and ERBB2 genes in squamous cell carcinoma and somatic mutations of ELF3 (13%) and CBFB (8%) genes in adenocarcinomas [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Mutations in the tumor suppressor gene TP53 and proto-oncogene PIK3CA and alterations of p53 and PIK3CA AKT mTOR pathways are common events in several human cancers. We focused on the analysis of TP53 and PIK3CA gene variations in adenocarcinoma, squamous cell carcinoma as well as in intraepithelial neoplasia grade 3 of the cervix.MethodsDNA samples from 28 cervical adenocarcinoma, 55 squamous cell carcinoma and 31 intraepithelial neoplasia grade 3 (CIN3), previously characterized in terms of human papillomavirus (HPV) prevalence and genotype distribution, were analyzed for TP53 and PIK3CA mutations in the exons 4¿9 and exon 9, respectively.ResultsSingle nucleotide substitutions in TP53 and PIK3CA genes were detected in 36% and 11% of adenocarcinoma, in 16% and in 5% of squamous cell carcinoma, and in 13% and none of CIN 3, respectively. Nucleotide changes in TP53 were significantly more frequent in adenocarcinoma cases than in squamous cell carcinoma and CIN3 (P¿=¿0.035) and were independent from HPV infection status.Conclusions Mutations in the TP53 gene and to lesser extent in the PIK3CA gene seem more frequent in cervical adenocarcinoma than in squamous cell carcinoma and CIN3. Whether TP53 and PIK3CA gene mutations have an impact on prognosis and response to molecularly targeted therapies as well as in cytotoxic drugs in different cervical cancer histotypes needs to be analyzed in investigative clinical trials.
    Full-text · Article · Sep 2014 · Journal of Translational Medicine
  • Source
    • "During productive HPV infections, transcription is tightly controlled by the binding of cellular transcription factors and the viral E2 gene product within the LCR in a differentiation dependent manner [16]. Integration of HPV DNA into the host genome frequently results in loss of E2 expression, relieving repression of the p97 promoter and leading to cellular transformation [14], although greater expression of HPV16 E6 and E7 has not been associated with HPV16 integration in vivo [17], and 28% of cervical cancers do not contain integrated HPV [18]. Some studies have reported E2 binding site (E2BS) methylation in association with cervical neoplasia and cancer , and suggest that methylation of E2BS might prevent E2 binding, resulting in increased expression of the E6 and E7 ORFs [7] [19] [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Methylation of HPV16 DNA is a promising biomarker for triage of HPV positive cervical screening samples but the biological basis for the association between HPV-associated neoplasia and increased methylation is unclear. Objectives To determine whether HPV16 DNA methylation was associated with viral integration, and investigate the relationships between viral DNA methylation, integration and gene expression. Study design : HPV16 DNA methylation, integration and gene expression were assessed using pyrosequencing, ligation-mediated PCR and QPCR, in biopsies from 25 patients attending a specialist vulval neoplasia clinic and in short-term clonal cell lines derived from vulval and vaginal neoplasia. Results Increased methylation of the HPV16 L1/L2 and E2 regions was associated with integration of viral DNA into the host genome. This relationship was observed both in vivo and in vitro. Increased methylation of E2 binding sites did not appear to be associated with greater expression of viral early genes. Expression of HPV E6 and E7 did not correlate with either integration state or increased L1/L2 methylation. Conclusions The data suggest that increased HPV DNA methylation may be partly attributable to viral integration, and provide a biological rationale for quantification of L1/L2 methylation in triage of HPV positive cervical screening samples.
    Full-text · Article · Aug 2014 · Journal of Clinical Virology
Show more